Relevant Data

Food Additives Approved in the United States:

Food Additives Approved by WHO:

  • BENZYL ACETATE [show]

General Information

Chemical nameBenzyl acetate
CAS number140-11-4
COE number204
JECFA number23
Flavouring typesubstances
FL No.09.014
MixtureNo
Purity of the named substance at least 95% unless otherwise specified
Reference bodyEFSA

From webgate.ec.europa.eu

Computed Descriptors

Download SDF
2D Structure
CID8785
IUPAC Namebenzyl acetate
InChIInChI=1S/C9H10O2/c1-8(10)11-7-9-5-3-2-4-6-9/h2-6H,7H2,1H3
InChI KeyQUKGYYKBILRGFE-UHFFFAOYSA-N
Canonical SMILESCC(=O)OCC1=CC=CC=C1
Molecular FormulaC9H10O2
Wikipediabenzyl acetate

From Pubchem


Computed Properties

Property Name Property Value
Molecular Weight150.177
Hydrogen Bond Donor Count0
Hydrogen Bond Acceptor Count2
Rotatable Bond Count3
Complexity126.0
CACTVS Substructure Key Fingerprint A A A D c c B w M A A A A A A A A A A A A A A A A A A A A A A A A A A w A A A A A A A A A A A B A A A A G g A A A A A A D A C g m A I y C I A A B A C I A i D S C A A C A A A g A A A I i A A A C I g I J i K A M R i C M A A k w A E I q A e A w C A O A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A = =
Topological Polar Surface Area26.3
Monoisotopic Mass150.068
Exact Mass150.068
Compound Is CanonicalizedTrue
Formal Charge0
Heavy Atom Count11
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Isotope Atom Count0
Covalently-Bonded Unit Count1

From Pubchem


Food Additives Biosynthesis/Degradation


ADMET Predicted Profile --- Classification

Model Result Probability
Absorption
Blood-Brain BarrierBBB+0.9811
Human Intestinal AbsorptionHIA+0.9964
Caco-2 PermeabilityCaco2+0.8681
P-glycoprotein SubstrateNon-substrate0.7339
P-glycoprotein InhibitorNon-inhibitor0.9635
Non-inhibitor0.9547
Renal Organic Cation TransporterNon-inhibitor0.8079
Distribution
Subcellular localizationMitochondria0.7946
Metabolism
CYP450 2C9 SubstrateNon-substrate0.7747
CYP450 2D6 SubstrateNon-substrate0.9247
CYP450 3A4 SubstrateNon-substrate0.7630
CYP450 1A2 InhibitorInhibitor0.7161
CYP450 2C9 InhibitorNon-inhibitor0.9360
CYP450 2D6 InhibitorNon-inhibitor0.9449
CYP450 2C19 InhibitorNon-inhibitor0.8875
CYP450 3A4 InhibitorNon-inhibitor0.9785
CYP Inhibitory PromiscuityLow CYP Inhibitory Promiscuity0.8211
Excretion
Toxicity
Human Ether-a-go-go-Related Gene InhibitionWeak inhibitor0.9596
Non-inhibitor0.9761
AMES ToxicityNon AMES toxic0.9133
CarcinogensNon-carcinogens0.6029
Fish ToxicityHigh FHMT0.9081
Tetrahymena Pyriformis ToxicityHigh TPT0.9760
Honey Bee ToxicityHigh HBT0.7535
BiodegradationReady biodegradable0.8789
Acute Oral ToxicityIII0.8584
Carcinogenicity (Three-class)Non-required0.7370

From admetSAR


ADMET Predicted Profile --- Regression

Model Value Unit
Absorption
Aqueous solubility-2.5577LogS
Caco-2 Permeability1.6748LogPapp, cm/s
Distribution
Metabolism
Excretion
Toxicity
Rat Acute Toxicity1.8747LD50, mol/kg
Fish Toxicity1.1705pLC50, mg/L
Tetrahymena Pyriformis Toxicity-0.1757pIGC50, ug/L

From admetSAR


Toxicity Profile

Route of ExposureOral ; inhalation ; dermal ; eye contact
Mechanism of ToxicityBenzyl acetate is a cholinesterase or acetylcholinesterase (AChE) inhibitor. A cholinesterase inhibitor (or 'anticholinesterase') suppresses the action of acetylcholinesterase. Because of its essential function, chemicals that interfere with the action of acetylcholinesterase are potent neurotoxins, causing excessive salivation and eye-watering in low doses, followed by muscle spasms and ultimately death. Nerve gases and many substances used in insecticides have been shown to act by binding a serine in the active site of acetylcholine esterase, inhibiting the enzyme completely. Acetylcholine esterase breaks down the neurotransmitter acetylcholine, which is released at nerve and muscle junctions, in order to allow the muscle or organ to relax. The result of acetylcholine esterase inhibition is that acetylcholine builds up and continues to act so that any nerve impulses are continually transmitted and muscle contractions do not stop. Among the most common acetylcholinesterase inhibitors are phosphorus-based compounds, which are designed to bind to the active site of the enzyme. The structural requirements are a phosphorus atom bearing two lipophilic groups, a leaving group (such as a halide or thiocyanate), and a terminal oxygen.
MetabolismParaoxonase (PON1) is a key enzyme in the metabolism of organophosphates. PON1 can inactivate some organophosphates through hydrolysis. PON1 hydrolyzes the active metabolites in several organophosphates insecticides as well as, nerve agents such as soman, sarin, and VX. The presence of PON1 polymorphisms causes there to be different enzyme levels and catalytic efficiency of this esterase, which in turn suggests that different individuals may be more susceptible to the toxic effect of OP exposure.
Toxicity ValuesLD50: 2490 mg/kg (Oral, Rat) LD50: 830 mg/kg (Oral, Mouse) LC50: 245 ppm over 8 hours (Inhalation, Cat)
Lethal DoseNone
Carcinogenicity (IARC Classification)3, not classifiable as to its carcinogenicity to humans.
Minimum Risk LevelNone
Health EffectsAcute exposure to cholinesterase inhibitors can cause a cholinergic crisis characterized by severe nausea/vomiting, salivation, sweating, bradycardia, hypotension, collapse, and convulsions. Increasing muscle weakness is a possibility and may result in death if respiratory muscles are involved. Accumulation of ACh at motor nerves causes overstimulation of nicotinic expression at the neuromuscular junction. When this occurs symptoms such as muscle weakness, fatigue, muscle cramps, fasciculation, and paralysis can be seen. When there is an accumulation of ACh at autonomic ganglia this causes overstimulation of nicotinic expression in the sympathetic system. Symptoms associated with this are hypertension, and hypoglycemia. Overstimulation of nicotinic acetylcholine receptors in the central nervous system, due to accumulation of ACh, results in anxiety, headache, convulsions, ataxia, depression of respiration and circulation, tremor, general weakness, and potentially coma. When there is expression of muscarinic overstimulation due to excess acetylcholine at muscarinic acetylcholine receptors symptoms of visual disturbances, tightness in chest, wheezing due to bronchoconstriction, increased bronchial secretions, increased salivation, lacrimation, sweating, peristalsis, and urination can occur. Certain reproductive effects in fertility, growth, and development for males and females have been linked specifically to organophosphate pesticide exposure. Most of the research on reproductive effects has been conducted on farmers working with pesticides and insecticdes in rural areas. In females menstrual cycle disturbances, longer pregnancies, spontaneous abortions, stillbirths, and some developmental effects in offspring have been linked to organophosphate pesticide exposure. Prenatal exposure has been linked to impaired fetal growth and development. Neurotoxic effects have also been linked to poisoning with OP pesticides causing four neurotoxic effects in humans: cholinergic syndrome, intermediate syndrome, organophosphate-induced delayed polyneuropathy (OPIDP), and chronic organophosphate-induced neuropsychiatric disorder (COPIND). These syndromes result after acute and chronic exposure to OP pesticides.
TreatmentIf the compound has been ingested, rapid gastric lavage should be performed using 5% sodium bicarbonate. For skin contact, the skin should be washed with soap and water. If the compound has entered the eyes, they should be washed with large quantities of isotonic saline or water. In serious cases, atropine and/or pralidoxime should be administered. Anti-cholinergic drugs work to counteract the effects of excess acetylcholine and reactivate AChE. Atropine can be used as an antidote in conjunction with pralidoxime or other pyridinium oximes (such as trimedoxime or obidoxime), though the use of '-oximes' has been found to be of no benefit, or possibly harmful, in at least two meta-analyses. Atropine is a muscarinic antagonist, and thus blocks the action of acetylcholine peripherally.
Reference

From T3DB


Taxonomic Classification

KingdomOrganic compounds
SuperclassBenzenoids
ClassBenzene and substituted derivatives
SubclassBenzyloxycarbonyls
Intermediate Tree NodesNot available
Direct ParentBenzyloxycarbonyls
Alternative Parents
Molecular FrameworkAromatic homomonocyclic compounds
SubstituentsBenzyloxycarbonyl - Carboxylic acid ester - Monocarboxylic acid or derivatives - Carboxylic acid derivative - Organic oxygen compound - Organic oxide - Hydrocarbon derivative - Organooxygen compound - Carbonyl group - Aromatic homomonocyclic compound
DescriptionThis compound belongs to the class of organic compounds known as benzyloxycarbonyls. These are organic compounds containing a carbonyl group substituted with a benzyloxyl group.

From ClassyFire


Targets

General Function:
Serine hydrolase activity
Specific Function:
Terminates signal transduction at the neuromuscular junction by rapid hydrolysis of the acetylcholine released into the synaptic cleft. Role in neuronal apoptosis.
Gene Name:
ACHE
Uniprot ID:
P22303
Molecular Weight:
67795.525 Da
References
  1. Dafforn A, Anderson M, Ash D, Campagna J, Daniel E, Horwood R, Kerr P, Rych G, Zappitelli F: The mode of binding of potential transition-state analogs to acetylcholinesterase. Biochim Biophys Acta. 1977 Oct 13;484(2):375-85. [20963 ]

From T3DB